AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...
AbbVie shares recently rebounded, supported by strong earnings, positive guidance, and a late 2024 dividend increase, indicating the potential for further gains. Despite a $3.5 billion impairment ...
AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...
AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. This time, the pharma is paying Xilio Therapeutics $52 million upfront to work on antibody-based ...
AbbVie CEO Robert Michael will soon add the role of board chairman to his résumé. Michael, who became CEO of the North Chicago-based pharmaceutical giant last summer, will assume duties as ...
NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback